NCT07155226: Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression
- State
- Under way
- Phase
- Phase 1 and Phase 2
- People
- 85 planned
- Started
- 9 Jan 2026
- Primary completion
- 15 Feb 2029
- Arms
- Module 1: AZD3632 dose 1, Module 1: AZD3632 dose 2, Module 1: AZD3632 dose 3, Module 1: AZD3632 dose 4, Module 1: AZD3632 dose 5, Module 1: AZD3632 dose 6
- Results
- None posted
- 4 Sep 2025: Trial registered
- 9 Jan 2026: Trial started